Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) therapy is beneficial for epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI)‐resistant non‐small cell lung cancer (NSCLC); however, the resistance mechanisms are not fully understood. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.